Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)
China
· Delayed Price · Currency is CNY 22.95
+0.42 (1.86%)
Apr 29, 2026, 3:00 PM CST
SHA:605033 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 911.95 | 881.01 | 694.02 | 905.41 | 841.93 | Upgrade
|
| Other Revenue | - | 4.52 | 5.01 | 0.63 | 0.56 | Upgrade
|
| Revenue | 911.95 | 885.53 | 699.03 | 906.05 | 842.49 | Upgrade
|
| Revenue Growth (YoY) | 2.98% | 26.68% | -22.85% | 7.54% | 48.19% | Upgrade
|
| Cost of Revenue | 599.62 | 654.14 | 478.04 | 528.82 | 532.38 | Upgrade
|
| Gross Profit | 312.33 | 231.39 | 220.99 | 377.23 | 310.11 | Upgrade
|
| Selling, General & Admin | 163.42 | 141.19 | 119.27 | 153.18 | 116.7 | Upgrade
|
| Research & Development | 84.93 | 74.33 | 58.53 | 80.04 | 63.81 | Upgrade
|
| Other Operating Expenses | -0.81 | 2.23 | 2.75 | 3.45 | 2.9 | Upgrade
|
| Operating Expenses | 247.55 | 212.51 | 178.09 | 242.66 | 187.05 | Upgrade
|
| Operating Income | 64.78 | 18.88 | 42.9 | 134.57 | 123.06 | Upgrade
|
| Interest Expense | - | -0.01 | -0.38 | -0.98 | -3.31 | Upgrade
|
| Interest & Investment Income | 6.32 | 9.33 | 6.58 | 6.86 | 2.61 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.02 | 0 | - | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.85 | -0.15 | -0.13 | -0.11 | 0.08 | Upgrade
|
| EBT Excluding Unusual Items | 72.95 | 28.07 | 48.97 | 140.34 | 122.5 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.87 | 0.47 | - | -0.07 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.04 | -0.04 | -0.12 | -0.02 | Upgrade
|
| Asset Writedown | -21.44 | 0 | 0.01 | - | - | Upgrade
|
| Other Unusual Items | - | 9.35 | 13.47 | 12.21 | 16.35 | Upgrade
|
| Pretax Income | 52.37 | 37.86 | 62.41 | 152.37 | 138.83 | Upgrade
|
| Income Tax Expense | 3.71 | 1 | 4.85 | 7.28 | 13.09 | Upgrade
|
| Net Income | 48.66 | 36.86 | 57.56 | 145.09 | 125.74 | Upgrade
|
| Net Income to Common | 48.66 | 36.86 | 57.56 | 145.09 | 125.74 | Upgrade
|
| Net Income Growth | 32.03% | -35.96% | -60.33% | 15.38% | 59.70% | Upgrade
|
| Shares Outstanding (Basic) | 135 | 137 | 134 | 136 | 110 | Upgrade
|
| Shares Outstanding (Diluted) | 135 | 137 | 134 | 136 | 110 | Upgrade
|
| Shares Change (YoY) | -0.98% | 1.99% | -1.29% | 22.93% | 9.27% | Upgrade
|
| EPS (Basic) | 0.36 | 0.27 | 0.43 | 1.07 | 1.14 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.27 | 0.43 | 1.07 | 1.14 | Upgrade
|
| EPS Growth | 33.33% | -37.21% | -59.81% | -6.14% | 46.15% | Upgrade
|
| Free Cash Flow | 44.74 | 121.59 | 131.1 | 17.12 | -215.28 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | 0.89 | 0.98 | 0.13 | -1.95 | Upgrade
|
| Dividend Per Share | - | 0.145 | 0.150 | 0.220 | 0.190 | Upgrade
|
| Dividend Growth | - | -3.33% | -31.82% | 15.79% | - | Upgrade
|
| Gross Margin | 34.25% | 26.13% | 31.61% | 41.63% | 36.81% | Upgrade
|
| Operating Margin | 7.10% | 2.13% | 6.14% | 14.85% | 14.61% | Upgrade
|
| Profit Margin | 5.34% | 4.16% | 8.23% | 16.01% | 14.92% | Upgrade
|
| Free Cash Flow Margin | 4.91% | 13.73% | 18.75% | 1.89% | -25.55% | Upgrade
|
| EBITDA | 97.43 | 39.31 | 63.77 | 150.05 | 135.54 | Upgrade
|
| EBITDA Margin | 10.68% | 4.44% | 9.12% | 16.56% | 16.09% | Upgrade
|
| D&A For EBITDA | 32.64 | 20.43 | 20.87 | 15.47 | 12.48 | Upgrade
|
| EBIT | 64.78 | 18.88 | 42.9 | 134.57 | 123.06 | Upgrade
|
| EBIT Margin | 7.10% | 2.13% | 6.14% | 14.85% | 14.61% | Upgrade
|
| Effective Tax Rate | 7.08% | 2.64% | 7.78% | 4.78% | 9.43% | Upgrade
|
| Revenue as Reported | - | 885.53 | 699.03 | 906.05 | 842.49 | Upgrade
|
| Advertising Expenses | - | 17.2 | 10.78 | 27.33 | 11.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.